608 related articles for article (PubMed ID: 29284597)
1. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
[TBL] [Abstract][Full Text] [Related]
2. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV
Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455
[TBL] [Abstract][Full Text] [Related]
3. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma.
Larson RC; Kann MC; Graham C; Mount CW; Castano AP; Lee WH; Bouffard AA; Takei HN; Almazan AJ; Scarfó I; Berger TR; Schmidts A; Frigault MJ; Gallagher KME; Maus MV
Nat Commun; 2023 Nov; 14(1):7509. PubMed ID: 37980341
[TBL] [Abstract][Full Text] [Related]
4. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.
Tran NL; Schneider P; Santiago-Raber ML
Eur J Immunol; 2017 Apr; 47(4):713-723. PubMed ID: 28267197
[TBL] [Abstract][Full Text] [Related]
5. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
[TBL] [Abstract][Full Text] [Related]
6. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
[TBL] [Abstract][Full Text] [Related]
7. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
8. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.
Alexaki VI; Pelekanou V; Notas G; Venihaki M; Kampa M; Dessirier V; Sabour-Alaoui S; Stathopoulos EN; Tsapis A; Castanas E
Endocrinology; 2012 Feb; 153(2):739-49. PubMed ID: 22166983
[TBL] [Abstract][Full Text] [Related]
9. Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties.
Schuepbach-Mallepell S; Das D; Willen L; Vigolo M; Tardivel A; Lebon L; Kowalczyk-Quintas C; Nys J; Smulski C; Zheng TS; Maskos K; Lammens A; Jiang X; Hess H; Tan SL; Schneider P
J Biol Chem; 2015 Jun; 290(26):16330-42. PubMed ID: 25953898
[TBL] [Abstract][Full Text] [Related]
10. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
Lee L; Lim WC; Galas-Filipowicz D; Fung K; Taylor J; Patel D; Akbar Z; Alvarez Mediavilla E; Wawrzyniecka P; Shome D; Reijmers RM; Gregg T; Wood L; Day W; Cerec V; Ferrari M; Thomas S; Cordoba S; Onuoha S; Khokhar N; Peddareddigari V; Al-Hajj M; Cavet J; Zweegman S; Rodriguez-Justo M; Youg K; Pule M; Popat R
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399355
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
[TBL] [Abstract][Full Text] [Related]
12. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
Yaccoby S; Pennisi A; Li X; Dillon SR; Zhan F; Barlogie B; Shaughnessy JD
Leukemia; 2008 Feb; 22(2):406-13. PubMed ID: 18046446
[TBL] [Abstract][Full Text] [Related]
13. Structural analysis of the inhibition of APRIL by TACI and BCMA through molecular dynamics simulations.
González-Mendióroz M; Alvarez-Vázquez AB; Rubio-Martinez J
J Mol Graph Model; 2013 Feb; 39():13-22. PubMed ID: 23202984
[TBL] [Abstract][Full Text] [Related]
14. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
15. TACI and endogenous APRIL in B cell maturation.
Garcia-Carmona Y; Fribourg M; Sowa A; Cerutti A; Cunningham-Rundles C
Clin Immunol; 2023 Aug; 253():109689. PubMed ID: 37422057
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
17. Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?
Xu S; Lam KP
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32340409
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells.
Ozcan E; Garibyan L; Lee JJ; Bram RJ; Lam KP; Geha RS
J Allergy Clin Immunol; 2009 Jun; 123(6):1277-86.e5. PubMed ID: 19427685
[TBL] [Abstract][Full Text] [Related]
20. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
